Preparation and Characterization of Methylene blue Nanoparticles for Alzheimer’s Disease and Other Tauopathies

Jinwal, Umesh K.; Groshev, Anastasia; Zhang, Juan; Grover, Aditya; Sutariya, Vijaykumar

doi:10.2174/1567201810666131113102037

Cited by 19 publications

(20 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The negative charge associated with the NPs suggests that the coating of GSH onto the NP surface may occur through an electrostatic interaction between the charge of GSH and the charge on the surface of the NPs. In addition, the negative charge associated with the NPs may suggest its extended suspension in the blood to allow for its permeation across the BBB (28).…”

Section: Discussionmentioning

confidence: 99%

Brain-Targeted Delivery of Docetaxel by Glutathione-Coated Nanoparticles for Brain Cancer

et al. 2014

Self Cite

View full text Add to dashboard Cite

Gliomas are some of the most aggressive types of cancers but the blood-brain barrier acts as an obstacle to therapeutic intervention in brain-related diseases. The blood-brain barrier blocks the permeation of potentially toxic compounds into neural tissue through the interactions of brain endothelial cells with glial cells (astrocytes and pericytes) which induce the formation of tight junctions in endothelial cells lining the blood capillaries. In the present study, we characterize a glutathione-coated docetaxel-loaded PEG-PLGA nanoparticle, show its in vitro drug release data along with cytotoxicity data in C6 and RG2 cells, and investigate its trans-blood-brain barrier permeation through the establishment of a Transwell cellular co-culture. We show that the docetaxel-loaded nanoparticle's size enables its trans-blood-brain barrier permeation; the nanoparticle exhibits a steady, sustained release of docetaxel; the drug is able to induce cell death in glioma models; and the glutathione-coated nanoparticle is able to permeate through the Transwell in vitro blood-brain barrier model.

show abstract

Section: Discussionmentioning

confidence: 99%

Brain-Targeted Delivery of Docetaxel by Glutathione-Coated Nanoparticles for Brain Cancer

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

“…A new formulation of Rember™ named LMTX™ provides MB in a stabilized, reduced “leuco-form”, which shows a higher absorbance from the intestine and therefore increases the effective dose of MB in the brain [ 4 , 33 , 34 ]. Another strategy is the development of MB-loaded hydrophobic nanoparticles suitable for blood-brain barrier permeation, which may provide a steady-state drug release instead of variable drug concentrations after intake of a single daily dose [ 87 ].…”

Section: Discussionmentioning

confidence: 99%

Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau

Hochgräfe

Sydow

Matenia

et al. 2015

acta neuropathol commun

113

View full text Add to dashboard Cite

show abstract

“…The incorporation of MB in biodegradable polymeric nanocarriers was investigated in several studies as a means to potentially improve bioavailability and patient compliance; provide controlled release; and to protect the die from enzymatic reduction and thus reduce required doses [ 107 , 110 , 111 ]. Some authors also suggested the incorporation of MB in polymeric NPs with the aim of potentially enhance its neuroprotective [ 110 ], anti-Alzheimer [ 112 ] and antitumor effect on glioblastoma [ 113 , 114 , 115 , 116 ]. Among these, Castañeda-Gill demonstrated that encapsulation of MB in PLGA NPs coated with Pluronic F68 (polyoxyethylene-polyoxypropylene-polyoxyethylene triblock copolymer) increased the BBB penetration ability of MB by 60% [ 117 ].…”

Section: Use Of Chitosan Nanoparticles In the Treatment Of Alzheimmentioning

confidence: 99%

“…Among these, Castañeda-Gill demonstrated that encapsulation of MB in PLGA NPs coated with Pluronic F68 (polyoxyethylene-polyoxypropylene-polyoxyethylene triblock copolymer) increased the BBB penetration ability of MB by 60% [ 117 ]. In the reports of Jinwal and Grover in vitro BBB Transwell™ studies confirmed that the glutathione-coated PLGA nano-encapsulated MB had more than 6.5-times higher permeation via a co-culture of RBE4 rat brain endothelial and C6 astrocytoma cells than the conventional MB solution 24 h after administration [ 112 , 114 ]. It was also found that the polymeric NP encapsulated MB effectively reduced both endogenous and over-expressed (by transfected HeLa cells) tau protein levels in human neuroblastoma SHSY-5Y cells.…”

Section: Use Of Chitosan Nanoparticles In the Treatment Of Alzheimmentioning

confidence: 99%

Use of Biodegradable, Chitosan-Based Nanoparticles in the Treatment of Alzheimer’s Disease

2020

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that affects more than 24 million people worldwide and represents an immense medical, social and economic burden. While a vast array of active pharmaceutical ingredients (API) is available for the prevention and possibly treatment of AD, applicability is limited by the selective nature of the blood-brain barrier (BBB) as well as by their severe peripheral side effects. A promising solution to these problems is the incorporation of anti-Alzheimer drugs in polymeric nanoparticles (NPs). However, while several polymeric NPs are nontoxic and biocompatible, many of them are not biodegradable and thus not appropriate for CNS-targeting. Among polymeric nanocarriers, chitosan-based NPs emerge as biodegradable yet stable vehicles for the delivery of CNS medications. Furthermore, due to their mucoadhesive character and intrinsic bioactivity, chitosan NPs can not only promote brain penetration of drugs via the olfactory route, but also act as anti-Alzheimer therapeutics themselves. Here we review how chitosan-based NPs could be used to address current challenges in the treatment of AD; with a specific focus on the enhancement of blood-brain barrier penetration of anti-Alzheimer drugs and on the reduction of their peripheral side effects.

show abstract

Preparation and Characterization of Methylene blue Nanoparticles for Alzheimer’s Disease and Other Tauopathies

Cited by 19 publications

References 33 publications

Brain-Targeted Delivery of Docetaxel by Glutathione-Coated Nanoparticles for Brain Cancer

Brain-Targeted Delivery of Docetaxel by Glutathione-Coated Nanoparticles for Brain Cancer

Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau

Use of Biodegradable, Chitosan-Based Nanoparticles in the Treatment of Alzheimer’s Disease

Contact Info

Product

Resources

About